联合检测血清 CA19-9、CA242、CEA对胰腺癌的诊断价值

摘要

目的：探讨肿瘤标志物 CA19-9、CA242、CEA 联合检测在胰腺癌诊断及疗效监测中的应用。方法采用美国 Beckman-coulter 公司生产的 DXI800化学发光仪对80例胰腺癌患者及80例正常对照组血清中的 CA19-9、CA242、CEA 水平进行检测。结果胰腺癌患者血清中 CA19-9、CA242、CEA 较正常对照组明显增高（P ＜0．01）， CA19-9、CA242、CEA 的阳性率分别为92．5％（74／80）、78．75％（63／80）、50．0％（40／80）。经手术治疗后 CA19-9的均值（44．6±20．4）u／ml 与手术前的 CA19-9的均值（215．8±56．6）u／ml 比较非常显著的降低（P ＜0．01）；CA242的均值（31．8±27．9）u／ml 与手术前的 CA242的均值（256．2±57．6）u／ml 比较非常显著的降低（P ＜0．01）；CEA 的均值（8．2±2．5）u／ml 与手术前的 CEA 的均值（27．3±12．4）u／ml 比较非常显著的降低（P ＜0．01）。结论 CA19-9、CA242、CEA 联合检测有助于提高胰腺癌的诊断符合率，同时也是对胰腺癌患者术后疗效监测的一种有效检测手段。%Objective to study the tumor markers CA19-9,CA242,CEA joint test in pancreatic cancer diagnosis and monitoring application.Methods using the American Beckman-coulter company produces the DXI800 chemilumines-cence apparatus on 80 cases of pancreatic cancer patients and80 patients with normal control group of serum CA19-9, CA242,CEA level testing.Results the pancreatic cancer patients serum CA19-9,CA242,CEA is significantly higher normal control group (P < 0.01 ),CA242 CA19-9,respectively,the CEA positie 92.5% (74/80),complications 78.75%(63/80),or 50.0% (40/80).By surgery after CA19-9 of the mean value (formed 44.6±20.4)u/ml and before surgery CA19-9 of the mean value (215.8±56.6)u/ml compare very significant reduction (P <0.01),CA242 mean (plus or minus 31.8±27.9)u/ml and before surgery CA242 mean (plus or minus 256.2±57.6)u/ml compare very significant reduction (P <0.01),The CEA mean (8.2 ± 2.5)u/ml and the CEA before operation of the mean value (27.3±12.4)u/ml compare very significant reduction (P <0.01).Conclusion CA19-9,CA242,CEA joint test help improve the diagnostic accuracy of pancreatic cancer,but also for pancreatic cancer patients postoperative curative effect of monitoring of an effective detection means.